Iovance Biotherapeutics (IOVA) reported a Q4 net loss late Thursday of $0.26 per diluted share, narrower than a loss of $0.45 a year earlier.

Analysts polled by FactSet expected a loss of $0.27.

Revenue for the quarter ended Dec. 31 was $73.7 million, compared with $482,000 a year earlier.

Analysts surveyed by FactSet expected $72.1 million.

The company reaffirmed its 2025 product revenue outlook of $450 million to $475 million.